Evaluation of the Molecular Mechanism of Chlorogenic Acid in the Treatment of Pulmonary Arterial Hypertension Based on Analysis Network Pharmacology and Molecular Docking
Open Access
- 5 January 2024
- journal article
- research article
- Published by MDPI AG in Journal of Vascular Diseases
- Vol. 3 (1) , 11-33
Abstract
Background: Pulmonary arterial hypertension (PAH) is a serious disease characterized by increased pressure in the pulmonary arteries, which can lead to heart failure and death. Chlorogenic acid (CGA) is a natural compound present in several foods and medicinal plants and has been described to exert a therapeutic effect in various diseases. However, its potential therapeutic effect on PAH remains undeciphered. In this study, the potential of CGA for the treatment of PAH was investigated using network pharmacology analysis and molecular docking. Methods: Potential CGA targets were obtained from the SwissTargetPrediction and GeneCards databases. Moreover, potential PAH targets were collected from the GeneCards and DisGNET databases. Then, common targets were selected, and a protein-protein network (PPI) was constructed between common CGA and PAH targets using the STRING database. The common hub targets were selected, and GO enrichment analysis was performed via KEGG using the DAVID 6.8 database. Additionally, molecular docking analysis was performed to investigate the interaction between CGA and these potential therapeutic targets. Results: We obtained 168 potential targets for CGA and 5779 potential targets associated with PAH. Among them, 133 were common to both CGA and PAH. The main hub targets identified through PPI network analysis were TP53, HIF1A, CASP3, IL1B, JUN, MMP9, CCL2, VEGFA, SRC, IKBKB, MMP2, CASP8, NOS3, MMP1, and CASP1. KEGG pathway analysis showed that these hub targets are associated with pathways such as lipid and atherosclerosis, fluid shear stress and atherosclerosis, and the IL-17 signaling pathway. In addition, the molecular docking results showed a high binding affinity between CGA and the 15 hub PAH-associated targets, further supporting its therapeutic potential. Conclusions: This study provides preliminary evidence on the underlying molecular mechanism of CGA in the treatment of PAH. The findings suggest that CGA could be a promising option for the development of new PAH drugs.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (270189, 772855, 773019)
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (270189, 772855, 773019)
This publication has 114 references indexed in Scilit:
- Nuclear Factor κ-B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial HypertensionPLOS ONE, 2013
- Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: Rapid Response to AnakinraCase Reports in Rheumatology, 2012
- Role of HIF-1α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosisBMC Pulmonary Medicine, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- c-Jun N-terminal kinase-dependent mechanisms in respiratory diseaseEuropean Respiratory Journal, 2006
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- The Protein Data BankNucleic Acids Research, 2000
- CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASESAnnual Review of Cell and Developmental Biology, 1997